Americana Partners LLC purchased a new position in Catalent, Inc. (NYSE:CTLT - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 9,736 shares of the company's stock, valued at approximately $590,000.
Other hedge funds also recently bought and sold shares of the company. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Catalent in the 2nd quarter valued at approximately $42,000. Longfellow Investment Management Co. LLC boosted its position in Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company's stock worth $55,000 after purchasing an additional 305 shares during the period. GAMMA Investing LLC lifted its stake in shares of Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company's stock worth $58,000 after buying an additional 212 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt grew its stake in Catalent by 1,400.0% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,500 shares of the company's stock valued at $91,000 after buying an additional 1,400 shares during the last quarter. Finally, Federated Hermes Inc. boosted its holdings in Catalent by 456.6% during the second quarter. Federated Hermes Inc. now owns 2,833 shares of the company's stock valued at $159,000 after acquiring an additional 2,324 shares during the period.
Catalent Price Performance
Shares of CTLT traded up $0.13 during trading hours on Friday, hitting $58.73. The stock had a trading volume of 1,704,242 shares, compared to its average volume of 2,040,898. Catalent, Inc. has a 52 week low of $32.38 and a 52 week high of $61.20. The stock has a market capitalization of $10.66 billion, a price-to-earnings ratio of -10.70, a P/E/G ratio of 2.07 and a beta of 1.15. The company's fifty day moving average is $60.06 and its two-hundred day moving average is $57.95. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96.
Catalent (NYSE:CTLT - Get Free Report) last posted its earnings results on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.44 by $0.13. The company had revenue of $1.30 billion during the quarter, compared to analysts' expectations of $1.23 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. On average, analysts anticipate that Catalent, Inc. will post 0.95 EPS for the current year.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on CTLT shares. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $63.50 price objective on shares of Catalent in a research report on Thursday, July 11th. Baird R W lowered Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. Robert W. Baird reiterated a "neutral" rating and set a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. William Blair reissued a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, StockNews.com started coverage on shares of Catalent in a report on Saturday, October 12th. They set a "hold" rating for the company. Nine research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $59.83.
View Our Latest Analysis on CTLT
Insider Activity at Catalent
In other news, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now directly owns 36,304 shares of the company's stock, valued at $2,177,150.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.31% of the stock is currently owned by company insiders.
About Catalent
(
Free Report)
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.
Featured Stories
Before you consider Catalent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalent wasn't on the list.
While Catalent currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
